Results 271 to 280 of about 249,886 (308)

Principles of Immunomodulatory Therapy

1994
This chapter concerns the principles of immunomodulatory therapy for use in the neurologic intensive care unit (ICU). These principles, which are derived from those generally used for patients receiving immunomodulatory therapy, are particularly important in the ICU.
David R. Cornblath, Reinhard Hohlfeld, Thomas P. Bleck   +2 more
openaire   +1 more source

Contemporary Immunomodulatory Therapy for Multiple Sclerosis

Journal of Neuro-Ophthalmology, 2001
Multiple sclerosis (MS) is no longer considered an unmanageable disease. Five drugs have obtained regulatory approval to safely and effectively modify the course of MS. Three preparations of interferon beta-Avonex (interferon beta-1a), Betaseron (interferon beta-1b), and Rebif (interferon beta 1a)-have shown efficacy in relapsing-remitting MS and show ...
openaire   +2 more sources

Immunomodulatory Therapies

2021
David E. Thurston, Ilona Pysz
openaire   +1 more source

Immunomodulatory Therapy for Multiple Sclerosis

2016
Substantial progress has been made over the past 25 years in terms of understanding the underlying pathophysiology, developing diagnostic and monitoring tools, and, most importantly, in the treatment of Multiple Sclerosis (MS) and its symptoms. Clinical trials have contributed greatly to this progress, as both successes and failures have helped ...
Irene Cortese, Avindra Nath
openaire   +1 more source

Hypophysitis associated with immunomodulatory therapies

2016
Learning objectives Background Findings and procedure details Conclusion Personal information ...
openaire   +1 more source

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul Parikh, Sagar Lonial
exaly  

Immunomodulatory therapies for cystic fibrosis.

Seminars in respiratory infections, 1993
Progressive pulmonary disease is the primary cause of morbidity and mortality in adult patients with cystic fibrosis (CF). The decrease in lung function associated with infection with Pseudomonas aeruginosa has been related to the severity of pulmonary inflammation.
A B, Thompson, W L, Smits, R B, Fick
openaire   +1 more source

Targeted Immunomodulatory Therapy: An Overview.

Rhode Island medical journal (2013), 2017
Monoclonal antibodies and other biologic response modifiers have allowed for targeted drug therapy in managing various autoimmune diseases. A number of immune pathways have been exploited in the development of targeted immunomodulatory therapies, including cytokine-directed therapies such as tumor necrosis factor-alpha and interleukins, integrins, B ...
Ashley L, Lefebvre, Laura, McAuliffe
openaire   +1 more source

Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians

Ca-A Cancer Journal for Clinicians, 2022
William A Hal, X Allen Li, Christopher Schultz   +2 more
exaly  

[Immunomodulatory therapy in multiple sclerosis].

Ideggyogyaszati szemle, 2005
During the past decade, several disease-modifying agents have been established and have become available for the treatment of multiple sclerosis. The disease-modifying agents could be grouped into immunomodulatory and immunosuppressive therapies altering the long-term course of multiple sclerosis.
Tünde, Csépány, Dániel, Bereczki
openaire   +1 more source